Longmont, CO, 3/28/2019

KromaTiD, Inc. announced today the opening of their new corporate headquarters, in Colorado’s Boulder County biotech hub. The new facility includes corporate offices as well as dedicated research, development and production laboratories, providing capacity to meet the growing demand for KromaTiD’s directional Genomic Hybridization (dGHTM) structural genomics products and data services.

There is a clear unmet need for single cell analysis of genomic structure in gene editing. “The new facility is a major milestone for KromaTiD” says Christopher Tompkins, PhD, KromaTiD’s President and Chief Executive Officer. “In addition to immediately expanding our capacity for dGHTM testing, we will be launching fully automated, high-throughput, whole genome structural genomics screening for the gene editing and undiagnosed disease markets.”

KromaTiD, Inc. is transforming the fields of gene editing, undiagnosed disease and oncology through discovery and detection of structural genomic changes. Based in Longmont, Colorado, KromaTiD markets a full suite of dGHTM and Pinpoint FISHTM products and services, including custom solutions, tailored to meet individual researchers needs.

KromaTiD’s new address is 1880 Industrial Drive, Suite A, Longmont, Colorado, 80501. For more information about KromaTiD, please call David Sebesta at 303-775-1512, or email david.sebesta@kromatid.com.